Evidence map›Paper›PMID 39920884›Full record

ArticleCPT: pharmacometrics & systems pharmacology2025

Elucidating Contributions of Drug Transporters/Enzyme to Nonlinear Pharmacokinetics of Grazoprevir by PBPK Modeling With a Cluster Gauss-Newton Method.

Takashi Yoshikado, Yasunori Aoki, Ryo Nakamura, Saeko Shida, Yuichi Sugiyama, Koji Chiba

Abstract read
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Takashi YoshikadoLaboratory of Clinical Pharmacology, Yokohama University of Pharmacy, Yokohama, Kanagawa, Japan.ORCID 0009-0003-2773-9761
Yasunori AokiLaboratory of Quantitative System Pharmacokinetics/Pharmacodynamics, School of Pharmacy, Josai International University, Tokyo, Japan.ORCID 0000-0002-5881-2023
Ryo NakamuraLaboratory of Clinical Pharmacology, Yokohama University of Pharmacy, Yokohama, Kanagawa, Japan.
Saeko ShidaLaboratory of Clinical Pharmacology, Yokohama University of Pharmacy, Yokohama, Kanagawa, Japan.
Yuichi SugiyamaLaboratory of Quantitative System Pharmacokinetics/Pharmacodynamics, School of Pharmacy, Josai International University, Tokyo, Japan.
Koji ChibaLaboratory of Clinical Pharmacology, Yokohama University of Pharmacy, Yokohama, Kanagawa, Japan.ORCID 0000-0001-7600-7813

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Grazoprevir (GZR), a direct-acting agent for hepatitis C virus, is recognized as a substrate for organic anion transporting polypeptide 1B (OATP1B), cytochrome P450 3A (CYP3A), and P-glycoprotein (P-gp). The objective of the present study was to elucidate the contribution of these molecules to the nonlinear pharmacokinetics of GZR using a physiologically based pharmacokinetic (PBPK) model. Utilizing plasma concentration-time profiles of GZR derived from reported dose-escalation (50-800 mg) clinical studies and cumulative excretion data, around 10 parameters, including Michaelis constants (K

Indexed as

Antiviral AgentsATP Binding Cassette Transporter, Subfamily B, Member 1Cytochrome P-450 CYP3AModels, BiologicalQuinoxalinesAmidesCarbamatesCyclopropanesHumansLactams, MacrocyclicLiver-Specific Organic Anion Transporter 1Nonlinear DynamicsSulfonamidesAmidesAntiviral AgentsATP Binding Cassette Transporter, Subfamily B, Member 1CarbamatesCyclopropanesCYP3A protein, humanCytochrome P-450 CYP3AgrazoprevirLactams, MacrocyclicLiver-Specific Organic Anion Transporter 1QuinoxalinesSLCO1B1 protein, humanSulfonamidesCYP3AMichaelis constantmiddle‐out approachnonlinear pharmacokineticsOATP1BPBPK modelingP‐gp

Identifiers

PMID39920884
PMCPMC12001266

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.